Elisabeth Bjork Sells 10,000 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) Director Elisabeth Bjork sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $29.32, for a total value of $293,200.00. Following the completion of the sale, the director directly owned 15,167 shares of the company’s stock, valued at approximately $444,696.44. This represents a 39.73% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Pharvaris Price Performance

Shares of PHVS opened at $29.68 on Friday. The firm has a market cap of $1.94 billion, a P/E ratio of -9.33 and a beta of -2.34. The stock has a 50 day simple moving average of $28.46 and a two-hundred day simple moving average of $26.81. Pharvaris N.V. has a 1 year low of $15.46 and a 1 year high of $33.33.

Pharvaris (NASDAQ:PHVS) last issued its earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.12. On average, equities analysts anticipate that Pharvaris N.V. will post -3.25 earnings per share for the current year.

Institutional Trading of Pharvaris

Institutional investors have recently made changes to their positions in the stock. GF Fund Management CO. LTD. purchased a new stake in shares of Pharvaris during the fourth quarter valued at approximately $35,000. Barclays PLC purchased a new stake in shares of Pharvaris during the fourth quarter valued at approximately $77,000. China Universal Asset Management Co. Ltd. purchased a new stake in Pharvaris in the third quarter worth $75,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Pharvaris in the fourth quarter worth $86,000. Finally, JPMorgan Chase & Co. lifted its stake in Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after acquiring an additional 783 shares during the period.

Wall Street Analysts Forecast Growth

PHVS has been the subject of several research reports. Royal Bank Of Canada cut their target price on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research note on Monday, April 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a research note on Tuesday, April 21st. Wolfe Research assumed coverage on Pharvaris in a research note on Thursday, April 9th. They set an “outperform” rating and a $42.00 price objective for the company. Citizens Jmp dropped their price objective on Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a research note on Wednesday, May 13th. Finally, UBS Group set a $74.00 price objective on Pharvaris in a research note on Wednesday, May 13th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $49.18.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.